Zinc-binding compounds induce cancer cell death via distinct modes of action

Cancer Letters

Volumn 271, Issue 2, 2008, Pages 251-259

  Ding, Wei Qun ^a   Yu, Hai Jun ^c   Lind, Stuart E ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c WUHAN UNIVERSITY   (China)

Author keywords

A2780; Chemotherapeutic; Clioquinol; PDTC; TPEN

Indexed keywords

CLIOQUINOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; PROTEIN KINASE B; PYRROLIDINE DITHIOCARBAMATE; ZINC;

ARTICLE; CANCER CELL; CELL DEATH; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; METAL BINDING; NECROSIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CLIOQUINOL; ETHYLENEDIAMINES; FEMALE; HUMANS; NF-KAPPA B; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRIAZENES; ZINC;

EID: 53249153476     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.06.011     Document Type: Article

References (43)

1. Huang R., Wallqvist A., and Covell D.G. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochem. Pharmacol. 69 (2005) 1009-1039
2. Lovejoy D.B., and Richardson D.R. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr. Med. Chem. 10 (2003) 1035-1049
3. Brewer G.J., Dick R.D., Grover D.K., LeClaire V., Tseng M., and Wicha M. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin. Cancer Res. 6 (2000) 1-10
4. Redman B.G., Esper P., Pan Q., Dunn R.L., Hussain H.K., Chenevert T., et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin. Cancer Res. 9 (2003) 1666-1672
5. Fraústo da Silva J.J.R., and Williams R.J.P. The Biological Chemistry of the Elements (2001), Oxford University Press, Oxford
6. Ding W.Q., Liu B., Vaught J.L., Yamauchi H., and Lind S.E. Anticancer activity of the antibiotic clioquinol. Cancer Res. 65 (2005) 3389-3395
7. Ding W.Q., Liu B., Vaught J.L., Palmiter R.D., and Lind S.E. Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol. Cancer Ther. 5 (2006) 1864-1872
8. Kim C.H., Kim J.H., Xu J., Hsu C.Y., and Ahn Y.S. Pyrrolidine dithiocarbamate induces bovine cerebral endothelial cell death by increasing the intracellular zinc level. J. Neurochem. 72 (1999) 1586-1592
9. 2+induced cortical neuronal death. Neuropharmacology 45 (2003) 420-428
10. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
11. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
12. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
13. Regland B., Lehmann W., Abedini I., Blennow K., Jonsson M., Karlsson I., et al. Treatment of Alzheimer's disease with clioquinol. Dement. Geriatr. Cogn. Disord. 12 (2001) 408-414
14. Topping R.J., and Jones M.M. Optimal dithiocarbamate structure for immunomodulator action. Med. Hypotheses 27 (1988) 55-57
15. Meyer M., Schreck R., and Baeuerle P.A. H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12 (1993) 2005-2015
16. Orrenius S., Nobel C.S., van den Dobbelsteen D.J., Burkitt M.J., and Slater A.F. Dithiocarbamates and the redox regulation of cell death. Biochem. Soc. Trans. 24 (1996) 1032-1038
17. Kim C.H., Kim J.H., Hsu C.Y., and Ahn Y.S. Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-kappaB activation. FEBS Lett. 449 (1999) 28-32
18. Chen Y.R., Shrivastava A., and Tan T.H. Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate. Oncogene 20 (2001) 367-374
19. Bartoli G.M., Muller A., Cadenas E., and Sies H. Antioxidant effect of diethyldithiocarbamate on microsomal lipid peroxidation assessed by low-level chemiluminescence and alkane production. FEBS Lett. 164 (1983) 371-374
20. Zanocco A.L., Pavez R., Videla L.A., and Lissi E.A. Antioxidant capacity of diethyldithiocarbamate in a metal independent lipid peroxidative process. Free Radic. Biol. Med. 7 (1989) 151-156
21. Nobel C.I., Kimland M., Lind B., Orrenius S., and Slater A.F. Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper. J. Biol. Chem. 270 (1995) 26202-26208
22. Burkitt M.J., Bishop H.S., Milne L., Tsang S.Y., Provan G.J., Nobel C.S., et al. Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species. Arch. Biochem. Biophys. 353 (1998) 73-84
23. Bach S.P., Chinery R., O'Dwyer S.T., Potten C.S., Coffey R.J., and Watson A.J. Pyrrolidinedithiocarbamate increases the therapeutic index of 5-fluorouracil in a mouse model. Gastroenterology 118 (2000) 81-89
24. Chinery R., Brockman J.A., Peeler M.O., Shyr Y., Beauchamp R.D., and Coffey R.J. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat. Med. 3 (1997) 1233-1241
25. Wu M., Lee H., Bellas R.E., Schauer S.L., Arsura M., Katz D., et al. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 15 (1996) 4682-4690
26. Della Ragione F., Cucciolla V., Borriello A., Della Pietra V., Manna C., Galletti P., et al. Pyrrolidine dithiocarbamate induces apoptosis by a cytochrome c-dependent mechanism. Biochem. Biophys. Res. Commun. 268 (2000) 942-946
27. Adler M., Shafer H., Hamilton T., and Petrali J.P. Cytotoxic actions of the heavy metal chelator TPEN on NG108-15 neuroblastoma-glioma cells. Neurotoxicology 20 (1999) 571-582
28. Hashemi M., Ghavami S., Eshraghi M., Booy E.P., and Los M. Cytotoxic effects of intra and extracellular zinc chelation on human breast cancer cells. Eur. J. Pharmacol. (2006)
29. Padmanabhan G., Becue I., and Smith J.B. Clioquinol. Anal. Profiles Drug Subst. 18 (1989) 57-90
30. Englert R.P., and Shacter E. Distinct modes of cell death induced by different reactive oxygen species: amino acyl chloramines mediate hypochlorous acid-induced apoptosis. J. Biol. Chem. 277 (2002) 20518-20526
31. Lee Y., and Shacter E. Bcl-2 does not protect Burkitt's lymphoma cells from oxidant-induced cell death. Blood 89 (1997) 4480-4492
32. Do T.N., Rosal R.V., Drew L., Raffo A.J., Michl J., Pincus M.R., et al. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene 22 (2003) 1431-1444
33. Yeung T.K., Germond C., Chen X., and Wang Z. The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem. Biophys. Res. Commun. 263 (1999) 398-404
34. Pommier Y., Sordet O., Antony S., Hayward R.L., and Kohn K.W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23 (2004) 2934-2949
35. 2+ chelating. Cell Struct. Funct. 23 (1998) 95-99
36. Costello L.C., Feng P., Milon B., Tan M., and Franklin R.B. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis. 7 (2004) 111-117
37. Abnet C.C., Lai B., Qiao Y.L., Vogt S., Luo X.M., Taylor P.R., et al. Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk. J. Natl. Cancer Inst. 97 (2005) 301-306
38. Begin M.E., Ells G., and Horrobin D.F. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J. Natl. Cancer Inst. 80 (1988) 188-194
39. Ding W.Q., Vaught J.L., Yamauchi H., and Lind S.E. Differential sensitivity of cancer cells to docosahexaenoic acid-induced cytotoxicity: the potential importance of down-regulation of superoxide dismutase 1 expression. Mol. Cancer Ther. 3 (2004) 1109-1117
40. Gonzalez M.J. Fish oil, lipid peroxidation and mammary tumor growth. J. Am. Coll. Nutr. 14 (1995) 325-335
41. Hardman W.E., Munoz Jr J., and Cameron I.L. Role of lipid peroxidation and antioxidant enzymes in omega 3 fatty acids induced suppression of breast cancer xenograft growth in mice. Cancer Cell Int. 2 (2002) 10
42. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 (2004) 633-645
43. Florent S., Malaplate-Armand C., Youssef I., Kriem B., Koziel V., Escanye M.C., et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J. Neurochem. 96 (2006) 385-395